Can Theranos pivot to become a blood test lab (if it hasn’t already)?  To see if their low prices can be sustainable, I compared some of them against Japan’s nationally mandated low fees. (Japan’s healthcare cost is 10% of GDP, as opposed to 17% in the US.) Above chart is the result. For 41 tests I compared, Theranos tests were 2.5 times more expensive on average than the same tests in Japan.   While this doesn’t prove Theranos-as-a-test-lab would work, it’s reassuring.

Continue reading →